Workforce Readiness in Bioprocessing

Overview

The growing mismatch between bioprocessing talent supply and the increasingly complex demands of AI, novel modalities, and advanced manufacturing, identified as a critical bottleneck. Cytiva Global Biopharma Index 2026 data shows 38% of bioprocessing industry respondents face critical or severe talent shortages for novel drug modality roles, with all categories worsening. The bioprocessing talent shortage affects national competitiveness, business viability, manufacturing resilience, supply chain security, and ultimately how quickly innovation reaches patients. (Segment 1 (00:00-05:00))